Claims
- 1. A polymeric composition comprising a mixture of at least one polyalkylene glycol (PAG) or PAG-based macromer, and at least one PAG-interacting polymer (PIP), wherein the PIP interacts with the PAG to produce a mixture having a greater viscosity than either the PAG or PIP.
- 2. The composition of claim 1, wherein the PIP is selected from the group consisting of glycosaminoglycans, celluloses, dextrans, and polyvinylpyrrolidone, and their salts and derivatives.
- 3. The composition of claim 2 wherein the PIP is selected from the group consisting of hyaluronic acid, carboxymethyl cellulose, dextran, dextran sulfate, and polyvinylpyrrolidone.
- 4. The composition of claim 1, wherein the polyalkylene glycol or PAG-based macromer is selected from the group consisting of polyethylene glycol, copolymers of ethylene glycol with propylene glycol, and PAGs with crosslinkable groups.
- 5. The composition of claim 4, wherein the PAG-based macromer is a PAG with crosslinkable groups selected from the group consisting of acrylate, succinimidate, and isocyanate.
- 6. The composition of claim 1, wherein the PAG-based macromer contains biodegradable linkages.
- 7. The composition of claim 1, wherein the PIP is hyaluronic acid and the PAG-based macromer is a PAG with crosslinkable groups.
- 8. The composition of claim 1, wherein the composition contains between about 0.05% and about 20% by weight of the PIP, and between about 4% and about 30% by weight of the polyalkylene glycol or PAG-based macromer.
- 9. A method for forming a biocompatible, flexible, bioadhesive gel, comprising
(a) forming an aqueous solution comprising a polyalkylene glycol or PAG-based macromer and a PAG-interacting polymer, wherein the PAG interacts with the PAG to increase the viscosity of the polymer solution; (b) applying the solution to the surface of a substrate, wherein the substrate is selected from the group consisting of cells, tissue surfaces and implants; and (c) polymerizing the solution to form a gel.
- 10. The method of claim 9, wherein the solution contains between about 0.05% and about 20% by weight of the PIP, and between about 4% and about 30% by weight of the polyalkylene glycol or PAG-based macromer.
- 11. The method of claim 9, wherein the solution further comprises a bioactive substance.
- 12. The method of claim 8, wherein the PIP is selected from the group consisting of glycosaminoglycans, celluloses, dextrans, and polyvinylpyrrolidone, and their salts and derivatives.
- 13. The method of claim 12 wherein the PIP is selected from the group consisting of hyaluronic acid, carboxymethyl cellulose, dextran, and dextran sulfate.
- 14. The method of claim 9, wherein the polyalkylene glycol or PAG-based macromer is selected from the group consisting of polyethylene glycol, copolymers of ethylene glycol with propylene glycol, and a PAG with crosslinkable groups.
- 15. The method of claim 9, wherein the gel is used in an application selected from the group consisting of formation of tissue coatings and tissue sealants; delivery of therapeutic substances; lubrication; filling voids; replacement of vitreous fluid; adherence of tissue to tissue or to a medical device; coating of a medical device; embolization; encapsulation of cells, tissues and organs; immobilization of cells, tissue and organs; treatment of the retina; treatment of joints; prevention of adhesions; regeneration of a tissue; and encapsulation of medications.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 60/253,477, filed Nov. 28, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60253477 |
Nov 2000 |
US |